Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus teriprizumab vs radiotherapy alone in elderly locally advanced nasopharyngeal carcinoma
ChiCTR2100051031Phase 3Recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of toripalimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Jiangxi Cancer Hospital. Primary endpoint: 2-year progression-free survival rate. Started Sep 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100051031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051031.